|
KMID : 0644320060110010023
|
|
Journal of Korean Oriental Oncology
2006 Volume.11 No. 1 p.23 ~ p.30
|
|
|
Study on antiangiogenic and antitumor activities of processed Rhus verniciflua Stokes extrac
|
|
Choi won-Cheol
Lee Jae-Ho
Lee Eun-Ok
Lee Hyo-Jung
Yoon Sung-Woo
Ahn Kyoo-Suk
Kim Sung-Hoon
|
|
|
Abstract
|
|
|
|
Rhus verniciflua Stokes has been used for treatment of blood stasis and abdominal mass in Oriental medicine. Rhus verniciflua Stokes has been experimentally reported to exert antioxidant, antiproliferative, antithrombotic and apoptotic activities. In the present study, the antiangiogenic and in vivo antitumor activities of aqueous extract of processed Rhus verniciflua Stokes (Nexia) by heat were examined to elucidate its anticancer mechanism. Nexia showed weak cytotoxiicty against human umbilical vein endothelial cells (HUVEC) and Lewis lung carcinoma cells (LLC) with IC50 of 200 ug/ml and >200 ug/ml, respectively. Nexia significantly inhibited the proliferation and migratory activity in vascular endothelial growth factor(VEGF) treated HUVEC. Furthermore, Nexia effectively suppressed the tumor volume in A549 nonsmall lung cancer bearing athymic nude mice, CanN. Cg-Foxn 1nu/CrljBgi up to 40.7% as well as tumor weight incised from LLC cells innoculated into the flank of C57BL/6 mice up to 50% compared with untreated control at a dose of 300 mg/kg. Taken together, these results suggest that processed Rhus verniciflua Stokes may inhibit the growth of Lewis lung carcinoma cells partly via inhibition of angiogenesis and can be potently applied to angiogenesis dependent cancers. However, it still needs a further research on molecular mechanism, angiogenesis animal study and clinical trial in future.
|
|
|
KEYWORD
|
|
|
processedRhusvernicifluaStokes, HUVEC, A549, LLC, angiogenesis, tumorgrowth
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|
|